Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
In his new role, Karthik will lead human capital strategy and HR operations across these regions
Former Global Head of IT & Digital Transformation at Biocon Biologics steps into enterprise-wide technology leadership role
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Move aligns global biologics identity under the Biocon Biologics brand
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Subscribe To Our Newsletter & Stay Updated
